Datopotamab deruxtecan (Dato-DXd) is an investigational TROP2-directed ADC ... TNBC and HR-positive, HER2-low or negative breast cancer. The programme includes seven phase III trials in lung cancer ...
One investigation discussed during the call involves sales reps in China allegedly changing genetic testing results to secure reimbursement for Tagrisso.
Following mixed study results, the partners have backed away from seeking broad clearance of dato-dxd in lung cancer and ...
Datopotamab deruxtecan (Dato-DXd) Datopotamab deruxtecan (Dato-DXd ... TNBC and HR-positive, HER2-low or negative breast cancer. The programme includes seven Phase III trials in lung cancer and five ...
LONDON — AstraZeneca said Tuesday it has had to resubmit a closely watched medicine for U.S. approval in a different form of ...
New Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has ...
Dato-DXd: Daiichi Sankyo, Inc. Datopotamab deruxtecan (Dato-DXd) is an investigational currently in Phase III for HR-positive ...
Narrow-moat Daiichi Sankyo is a Japanese drugmaker with a global footprint and cutting-edge development platform for antibody drug conjugates. As an established pharmaceutical company with a long ...
The first patients have been dosed in three global, randomized phase 3 trials evaluating the efficacy and safety of datopotamab deruxtecan (Dato-DXd)- ...
8,9 About Datopotamab Deruxtecan (Dato-DXd) Datopotamab deruxtecan (Dato ... triple negative breast cancer and HR positive, HER2 negative breast cancer. The program includes seven phase 3 trials ...
randomized phase 3 trials evaluating the efficacy and safety of datopotamab deruxtecan (Dato-DXd)-based combinations in patients with locally advanced or metastatic nonsquamous non-small cell lung ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback